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United StatesThe importance of our world's constant changewas famously recog-
nized by Heraclitus of Ephesus (535 BC–475 BC), who is quoted as say-
ing that because of such change one cannot step into the same river
twice (Plato). Heraclitus' disciple, Cratylus, supposedly one-upped his
master by noting that because of the constant ﬂow, one cannot step
into the same river even once! Today, these views can inform our un-
derstanding of cancer, a disease that continuously changes as it selects
for increasingly proliferative cells. FromHeraclitus' standpoint, evaluat-
ing a cancermay be akin to entering a fastmoving and constantly evolv-
ing current. However, despite this recognition, it can be difﬁcult to grasp
how cancers change, and especially whether they change in predictable
or in unpredictable ways. In this issue of EBioMedicine, Josephine
Dorsman and colleagues show that it is possible to use gene expression
proﬁling to outline the channels through which certain cancers repro-
ducibly ﬂow (Kooi et al., 2015).
Kooi, Mol et al. focused on the childhood retinal cancer retinoblasto-
ma, which is usually initiated by biallelic inactivation of RB1. The au-
thors ﬁrst used hierarchical clustering of gene expression proﬁles to
determine if retinoblastomas comprise a single “type,” as proposed by
one group (McEvoy et al., 2011), or comprise distinct subtypes, as sug-
gested by another (Kapatai et al., 2013). Unsatisfyingly, they found
that retinoblastomas either could be divided into two groups or could
form a continuum of phenotypes, depending upon which clustering al-
gorithm was used. However, using the algorithm that yielded two
groups, they found that the genes distinguishing the groups varied con-
tinuously rather than dichotomously across all retinoblastoma samples,
implying that their division into groups was artiﬁcial. One end of the
tumor spectrum had a strong photoreceptor signature, whereas the
other end had M-phase and mRNA and ribosome synthesis (RNA bio-
genesis) signatures, and these signatures varied inversely as well as
continuously across the spectrum. Moreover, tumors with higher
“photoreceptorness” had smaller size, younger age at diagnosis, in-
creased histologic differentiation, and fewer somatic DNA copy number
alterations (SCNAs), compared to those with higher M phase and RNA
biogenesis phenotypes. The ﬁndings indicate that retinoblastomas
progress from smaller,more differentiated, andmore genomically intact
tumors towards larger, less differentiated andmore genomically altered
tumors likely having greater proliferative potential.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.022.
http://dx.doi.org/10.1016/j.ebiom.2015.07.023
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article underOne implication of this progressionmodel is that RB1−/− retinoblas-
tomas are likely to have a single cell of origin, rather than different ori-
gins for the now unlikely different subtypes. Notably, Kooi, Mol et al.
found that differentiated tumors highly expressed cone-speciﬁc but
not rod-speciﬁc genes, consistentwith a proposed coneprecursor origin
followed bydedifferentiation (Xu et al., 2014). Theﬁndings are also con-
sistent with a model in which the earliest RB1−/− lesions are self-
limited (as well as cone-like (Xu et al., 2009)) retinomas that subse-
quently convert to retinoblastoma and acquire SCNAs (Dimaras et al.,
2008). Importantly, the lack of SCNAs in themost differentiated tumors
(Kooi et al., 2015) conﬁrms prior evidence that recurrent SCNAs are not
needed for retinoblastoma development (Zhang et al., 2012). Thus, the
basis for the conversion of retinoma to differentiated retinoblastoma re-
mains unclear.
Kooi, Mol et al. also shed light on the rare retinoblastomas driven by
MYCN ampliﬁcation (MYCNA) rather than by RB1 loss (Rushlow et al.,
2013). AlthoughMYCNA,RB1+/+ tumors have distinct histology, earlier
onset, and possibly more aggressive behavior (Rushlow et al., 2013),
the two examples in the Kooi, Mol et al. cohort fell within the
photoreceptorness and M phase and RNA biogenesis signature spec-
trum of RB1−/− tumors. However, they also differentially expressed
many cell cycle and other genes, bringing into question whether they
have a distinct cell of origin or have the same origin but are phenotypi-
cally modulated by theirMYCN ampliﬁcation and retained pRB.
Finally, the study has interesting clinical implications. Surprisingly,
differentiation status did not correlate with optic nerve or choroidal in-
vasion, nor with retinoblastoma stage, implying that cellular evolution
does not underlie current clinical progression metrics. Moreover, upon
explant, the less differentiated tumors were on average more sensitive
to several chemotherapeutic agents. While the high variability of the
drug responses and limitations of ex vivo culture preclude direct clinical
translation, the recognition that drug sensitivity evolves in a predictable
manner is a ﬁrst step towards targeting the distinct cellular entities.
While Kooi, Mol et al. make a strong case for retinoblastoma progres-
sion, mechanistic questions remain. For example, it is unclear whether
most of the early retinoblastoma cells gradually dedifferentiate or if
only rare cells dedifferentiate and then gradually overgrow their counter-
parts. It is also unproven whether speciﬁc SCNAs mediate the decreased
photoreceptorness and increased M-phase and RNA biogenesis-related
gene expression. The mechanism underlying these gene expressionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
624 D. Cobrinik / EBioMedicine 2 (2015) 623–624changes is of great interest since similar changes may contribute to pro-
gression of other malignancies.
While the current ﬁndings clearly change our understanding of ret-
inoblastoma, cancer researchers have stepped into similar rivers before.
In the 1980s, it was recognized that progression of colorectal cancer
from early adenoma to carcinoma andmetastatic diseasewas accompa-
nied by speciﬁc genetic changes (Fearon and Vogelstein, 1990), and
similar progression has been noted in many other malignancies. But
the Dorsman group's study is unusual in that progression states were
discerned primarily through gene expression proﬁling rather than
through histopathological criteria, and they portend an era when
targeted therapies may be tailored to attack the predictable cellular
states through which cancers evolve. The lesson is that cancers can
progress in predictable ways. We must embrace this lesson and use it
to our advantage.
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